# ðŸ“ˆ eyentelligence: 3-5 Year Business Plan

**Company**: eyentelligence  
**Planning Period**: Year 2-5 (Months 13-60)  
**Strategic Goal**: Build sustainable, high-growth dual-platform company

---

## Executive Summary

### Vision for Year 5
**eyentelligence becomes the leading platform for mechanistic biological simulation AND privacy-first professional services AI**, with:

- **cognisom**: Industry-standard research platform, $5-10M annual revenue
- **eyentell**: Market-leading SaaS for professional services, $10-20M ARR
- **Combined**: $15-30M revenue, 50-100 employees, profitable or Series B funded
- **Impact**: 10,000+ researchers using cognisom, 5,000+ professionals using eyentell

### Strategic Positioning
- **cognisom**: "The GPU-accelerated platform for cellular biology"
- **eyentell**: "The privacy-first AI platform for trusted professionals"
- **eyentelligence**: "Understanding communication from cells to minds"

---

## Year 2: Validation & Growth (Months 13-24)

### Strategic Objectives
1. **Validate commercial models** for both platforms
2. **Scale revenue** to $500K-1M combined
3. **Build core team** (5-10 people)
4. **Establish market position** in both domains

---

### cognisom: Year 2 Plan

#### **Q1-Q2 (Months 13-18): Commercial Validation**

**Product Development**
- Multi-GPU scaling (10-100K cells â†’ 1M+ cells)
- ML surrogate models (3-10Ã— speedup)
- Prostate cancer full model
- Pancreatic cancer (PDAC) extension
- Commercial features (enterprise support, SLAs)

**Go-to-Market**
- **Academic**: 50-100 active users
  - 5-10 major research institutions
  - 2-3 publications in high-impact journals
  - Conference presentations (GTC, AACR, ASCB)

- **Commercial**: First pharma pilots
  - 2-3 pilot projects ($50K-100K each)
  - Drug screening applications
  - Treatment optimization studies
  - Success metrics: 1-2 conversions to full licenses

**Team**
- Hire CUDA engineer (full-time)
- Hire computational biologist (full-time)
- Add 2-3 advisors (cancer biology, pharma)

**Revenue Target**: $300K-500K
- Grants: $200K-300K (NIH R01, NSF)
- Consulting: $50K-100K
- Pilot projects: $50K-100K

#### **Q3-Q4 (Months 19-24): Scale & Partnerships**

**Product Development**
- Patient-specific modeling (genomic data integration)
- Clinical trial simulation
- Real-time visualization improvements
- API for third-party integrations
- SaaS platform beta (cloud-hosted)

**Go-to-Market**
- **Academic**: 100-200 users
  - 10-20 institutions
  - 5-10 publications
  - Community contributions (open-source)

- **Commercial**: Scale pharma partnerships
  - 5-10 active commercial projects
  - 2-3 annual licenses ($100K-300K each)
  - Partnership with CRO or drug discovery platform

**Team**
- Hire ML scientist (full-time)
- Hire technical writer/community manager
- Expand advisor network

**Revenue Target**: $500K-800K
- Grants: $200K-300K
- Commercial licenses: $200K-400K
- Consulting: $100K-100K

#### **Year 2 Total (cognisom)**: $800K-1.3M revenue

---

### eyentell: Year 2 Plan

#### **Q1-Q2 (Months 13-18): Product-Market Fit â†’ Growth**

**Product Development**
- Advanced AI triage (GPT-4 integration)
- Voice call transcription + analysis
- Automated intake form generation
- Client portal (self-service)
- Mobile app (iOS/Android)
- Integrations (Calendly, Stripe, QuickBooks)

**Go-to-Market**
- **Customer Acquisition**
  - Scale to 200-300 customers
  - CAC target: <$400
  - Channels: Content marketing, paid ads, partnerships
  - Referral program (20% of new customers)

- **Market Expansion**
  - Launch in 2-3 new verticals
    - Estate planning attorneys
    - Immigration lawyers
    - Marriage/family therapists
  - Geographic expansion (start with US, test Canada/UK)

**Team**
- Hire product manager
- Hire customer success manager
- Hire 2 full-stack engineers
- Marketing contractor â†’ full-time hire

**Revenue Target**: $30K-50K MRR by Month 18
- 200-300 customers
- Average $150/month (mix of plans)
- Annual contracts: 30-40% of customers
- **Quarterly revenue**: $270K-450K

#### **Q3-Q4 (Months 19-24): Scale Operations**

**Product Development**
- Enterprise features (SSO, custom branding)
- Advanced analytics and reporting
- Compliance automation (HIPAA, state bar rules)
- AI assistant for professionals (draft responses, summaries)
- Workflow automation

**Go-to-Market**
- **Customer Acquisition**
  - Scale to 500-700 customers
  - Expand paid advertising
  - Partnership with 5-10 professional associations
  - Webinar series (1-2 per month)

- **Customer Success**
  - Dedicated success team
  - Onboarding program
  - Training webinars
  - Customer advisory board

**Team**
- Hire 2 more engineers
- Hire sales development rep (SDR)
- Expand customer success (2-3 people)

**Revenue Target**: $70K-100K MRR by Month 24
- 500-700 customers
- Average $140-150/month
- Annual contracts: 50% of customers
- **Quarterly revenue**: $630K-900K

#### **Year 2 Total (eyentell)**: $900K-1.35M ARR

---

### Year 2 Summary

| Metric | cognisom | eyentell | Combined |
|--------|----------|----------|----------|
| **Revenue** | $800K-1.3M | $900K-1.35M | $1.7M-2.65M |
| **Customers/Users** | 100-200 | 500-700 | 600-900 |
| **Team Size** | 5-7 | 6-8 | 11-15 |
| **Cash Flow** | Break-even | Profitable | Profitable |

**Key Milestone**: Cross $2M combined revenue, achieve profitability or raise Series A

---

## Year 3: Scale & Market Leadership (Months 25-36)

### Strategic Objectives
1. **Establish market leadership** in both categories
2. **Scale to $5-10M revenue** combined
3. **Build scalable operations** (20-30 people)
4. **Expand internationally** (eyentell)

---

### cognisom: Year 3 Plan

#### **Product Strategy**
- **Multi-organ modeling** (beyond prostate/pancreas)
  - Breast cancer
  - Lung cancer
  - Colon cancer
- **Digital twin platform** (patient-specific models)
- **Drug discovery suite** (virtual screening, optimization)
- **Clinical decision support** (treatment prediction)

#### **Go-to-Market Strategy**

**Academic Market**
- 500-1,000 active users
- 50+ institutions worldwide
- 20-30 publications annually
- Community-driven development
- Annual user conference (virtual/hybrid)

**Commercial Market**
- **Pharma/Biotech**: 10-20 enterprise customers
  - Annual licenses: $200K-500K each
  - Multi-year contracts
  - Custom development services
  - Target: Top 20 pharma companies

- **Clinical**: Early adopter programs
  - Partner with 3-5 cancer centers
  - Clinical trial support
  - Treatment optimization pilots
  - Regulatory pathway (FDA clearance)

**SaaS Platform**
- Cloud-hosted simulations
- Pay-per-compute model
- Managed services
- Target: 100-200 SaaS customers at $500-5K/month

#### **Revenue Model**
| Source | Q1 | Q2 | Q3 | Q4 | Year Total |
|--------|----|----|----|----|------------|
| Grants | $150K | $150K | $200K | $200K | $700K |
| Enterprise Licenses | $400K | $500K | $600K | $700K | $2.2M |
| SaaS Platform | $50K | $100K | $150K | $200K | $500K |
| Consulting | $100K | $150K | $150K | $200K | $600K |
| **Total** | **$700K** | **$900K** | **$1.1M** | **$1.3M** | **$4M** |

#### **Team Expansion**
- **Engineering**: 6-8 people (CUDA, ML, backend, frontend)
- **Science**: 3-4 people (comp bio, validation, publications)
- **Commercial**: 2-3 people (sales, partnerships, customer success)
- **Operations**: 1-2 people (finance, HR, legal)
- **Total**: 12-17 people for cognisom

---

### eyentell: Year 3 Plan

#### **Product Strategy**
- **AI-powered features**
  - Predictive client risk assessment
  - Automated document generation
  - Intelligent scheduling
  - Sentiment analysis (client communications)

- **Platform expansion**
  - White-label solution (for associations)
  - API for third-party developers
  - Marketplace (integrations, templates)

- **Compliance & security**
  - SOC 2 Type II certification
  - HIPAA compliance audit
  - State-specific compliance (bar rules, licensing)

#### **Go-to-Market Strategy**

**Customer Acquisition**
- Scale to 2,000-3,000 customers
- Multi-channel approach:
  - Inbound (SEO, content): 40%
  - Paid advertising: 30%
  - Partnerships: 20%
  - Referrals: 10%

**Market Expansion**
- **Vertical expansion**
  - Add 3-5 new professional categories
  - Financial advisors
  - Social workers
  - Mediators
  - Career counselors

- **Geographic expansion**
  - Canada (Q1-Q2)
  - UK (Q3-Q4)
  - Australia (Q4)

**Enterprise segment**
- Target mid-size firms (10-50 people)
- Custom pricing: $500-2,000/month
- Dedicated account management
- Custom workflows and integrations

#### **Revenue Model**
| Segment | Customers | ARPU | MRR | ARR |
|---------|-----------|------|-----|-----|
| Solo | 1,500 | $59 | $88.5K | $1.06M |
| Small Practice | 400 | $179 | $71.6K | $859K |
| Professional | 100 | $349 | $34.9K | $419K |
| Enterprise | 20 | $1,200 | $24K | $288K |
| **Total** | **2,020** | **$108** | **$219K** | **$2.63M** |

**Year 3 Target**: $2.5M-3M ARR

#### **Team Expansion**
- **Engineering**: 6-8 people (full-stack, mobile, ML)
- **Product**: 2-3 people (PM, design, UX research)
- **Sales & Marketing**: 4-5 people (SDRs, marketing, content)
- **Customer Success**: 4-5 people (onboarding, support, success)
- **Operations**: 2-3 people (finance, HR, legal, compliance)
- **Total**: 18-24 people for eyentell

---

### Year 3 Summary

| Metric | cognisom | eyentell | Combined |
|--------|----------|----------|----------|
| **Revenue** | $4M | $2.5M-3M | $6.5M-7M |
| **Customers/Users** | 500-1,000 | 2,000-3,000 | 2,500-4,000 |
| **Team Size** | 12-17 | 18-24 | 30-41 |
| **Gross Margin** | 70-80% | 80-85% | 75-82% |
| **EBITDA** | Break-even | 20-30% | 10-20% |

**Key Milestone**: $7M revenue, profitable operations, clear path to $20M+

---

## Year 4-5: Market Dominance & Optionality (Months 37-60)

### Strategic Objectives
1. **Dominate respective markets** (top 3 in each category)
2. **Scale to $15-30M revenue** combined
3. **Build world-class team** (50-100 people)
4. **Create strategic optionality** (IPO, acquisition, or continue growth)

---

### cognisom: Year 4-5 Vision

#### **Product Evolution**
- **Whole-body modeling** (multi-organ systems)
- **AI-accelerated simulations** (ML surrogates, 100Ã— speedup)
- **Clinical platform** (FDA-cleared decision support)
- **Drug discovery platform** (integrated with pharma workflows)
- **Educational platform** (university licensing)

#### **Market Position**
- **Academic**: Industry standard
  - 2,000-5,000 active users
  - 100+ institutions
  - 100+ publications annually citing platform
  - Textbook integration

- **Commercial**: Essential tool for drug discovery
  - 30-50 enterprise customers
  - Embedded in pharma R&D workflows
  - Strategic partnerships with CROs
  - Integration with lab automation

- **Clinical**: Emerging standard of care
  - 10-20 cancer centers using platform
  - Clinical trial optimization
  - Treatment response prediction
  - FDA clearance for specific indications

#### **Revenue Trajectory**

**Year 4**: $6M-8M
- Enterprise licenses: $3M-4M (20-30 customers)
- SaaS platform: $1M-1.5M (200-300 customers)
- Grants: $800K-1M (sustained funding)
- Consulting/services: $1M-1.5M

**Year 5**: $8M-12M
- Enterprise licenses: $4M-6M (30-50 customers)
- SaaS platform: $2M-3M (400-600 customers)
- Grants: $1M-1.5M
- Consulting/services: $1M-1.5M

#### **Team Growth**
- **Year 4**: 20-25 people
  - Engineering: 10-12
  - Science: 5-6
  - Commercial: 3-4
  - Operations: 2-3

- **Year 5**: 25-35 people
  - Engineering: 12-15
  - Science: 6-8
  - Commercial: 4-6
  - Operations: 3-6

---

### eyentell: Year 4-5 Vision

#### **Product Evolution**
- **AI co-pilot** for professionals
  - Real-time assistance during sessions
  - Automated documentation
  - Predictive insights
  - Outcome tracking

- **Platform ecosystem**
  - Third-party app marketplace
  - White-label for associations
  - API for enterprise integrations
  - Data analytics platform

- **Vertical-specific solutions**
  - Legal practice management
  - Mental health EHR
  - Counseling platform
  - Each with specialized features

#### **Market Position**
- **Market leader** in privacy-first professional AI
- **10,000+ customers** across multiple verticals
- **International presence** (US, Canada, UK, Australia, EU)
- **Enterprise segment** (500+ user organizations)

#### **Revenue Trajectory**

**Year 4**: $6M-10M ARR
- 5,000-7,000 customers
- Average ARPU: $100-120/month
- Enterprise: 50-100 customers at $1K-3K/month
- International: 20-30% of revenue

**Year 5**: $10M-18M ARR
- 8,000-12,000 customers
- Average ARPU: $105-125/month
- Enterprise: 100-200 customers
- International: 30-40% of revenue
- White-label: 5-10 associations

#### **Team Growth**
- **Year 4**: 30-40 people
  - Engineering: 10-12
  - Product: 3-4
  - Sales & Marketing: 8-10
  - Customer Success: 6-8
  - Operations: 3-6

- **Year 5**: 40-60 people
  - Engineering: 12-16
  - Product: 4-6
  - Sales & Marketing: 12-16
  - Customer Success: 8-12
  - Operations: 4-10

---

### Year 4-5 Combined Projections

#### **Revenue Growth**

| Year | cognisom | eyentell | Combined | Growth |
|------|----------|----------|----------|--------|
| Year 3 | $4M | $2.5M-3M | $6.5M-7M | - |
| Year 4 | $6M-8M | $6M-10M | $12M-18M | 85-157% |
| Year 5 | $8M-12M | $10M-18M | $18M-30M | 50-67% |

#### **Team Growth**

| Year | cognisom | eyentell | Combined |
|------|----------|----------|----------|
| Year 3 | 12-17 | 18-24 | 30-41 |
| Year 4 | 20-25 | 30-40 | 50-65 |
| Year 5 | 25-35 | 40-60 | 65-95 |

#### **Financial Metrics (Year 5)**

| Metric | Target |
|--------|--------|
| **Revenue** | $18M-30M |
| **Gross Margin** | 75-85% |
| **EBITDA Margin** | 15-25% |
| **Cash Flow** | $3M-7M positive |
| **Runway** | 18-24 months |

---

## Strategic Optionality (Year 5+)

### Option 1: Continue Independent Growth
**Scenario**: Strong profitability, sustainable growth

**Strategy**:
- Maintain 30-50% annual growth
- Expand internationally
- Add adjacent products
- Build towards $100M+ revenue

**Pros**:
- Maintain control
- Build long-term value
- Flexibility

**Cons**:
- Slower growth
- Competitive pressure
- Capital constraints

### Option 2: Raise Series B/C
**Scenario**: Accelerate growth, expand market share

**Strategy**:
- Raise $20M-50M
- Aggressive hiring
- International expansion
- M&A opportunities

**Valuation**: $100M-300M (5-10Ã— revenue)

**Pros**:
- Fuel rapid growth
- Competitive moat
- Attract top talent

**Cons**:
- Dilution
- Investor pressure
- Loss of control

### Option 3: Strategic Acquisition
**Scenario**: Attractive offer from strategic buyer

**Potential Acquirers**:
- **cognisom**: Pharma (Roche, Novartis), Tech (NVIDIA, Google), Biotech platforms (Recursion, Insitro)
- **eyentell**: Healthcare IT (Epic, Cerner), Legal tech (Clio, MyCase), Mental health (Headspace, Talkspace)

**Valuation**: $150M-500M (8-15Ã— revenue)

**Pros**:
- Liquidity for founders/team
- Resources to scale faster
- Strategic synergies

**Cons**:
- Loss of independence
- Cultural integration
- Mission drift risk

### Option 4: IPO
**Scenario**: Strong growth, large market, public readiness

**Requirements**:
- $50M+ revenue
- 40%+ growth rate
- Strong unit economics
- Experienced management team

**Timeline**: Year 6-8

**Pros**:
- Maximum valuation
- Liquidity
- Currency for M&A

**Cons**:
- Regulatory burden
- Public scrutiny
- Short-term pressure

---

## Key Success Factors

### Product Excellence
1. **cognisom**: Scientific rigor, performance, usability
2. **eyentell**: Privacy, AI quality, user experience
3. **Both**: Continuous innovation, customer feedback

### Market Execution
1. **Clear positioning**: Own distinct categories
2. **Strong brand**: Thought leadership, community
3. **Efficient GTM**: Scalable acquisition, high retention

### Team & Culture
1. **Attract top talent**: Mission-driven, competitive comp
2. **Retain key people**: Equity, growth opportunities, culture
3. **Scale culture**: Values, processes, communication

### Financial Discipline
1. **Unit economics**: CAC < 12 months payback, LTV:CAC > 3:1
2. **Cash management**: 12-18 months runway minimum
3. **Profitability path**: Clear route to sustainable margins

### Strategic Partnerships
1. **cognisom**: Pharma, academic institutions, NVIDIA
2. **eyentell**: Professional associations, complementary SaaS
3. **Both**: Distribution, co-marketing, integration

---

## Risk Management (Years 3-5)

### Market Risks

#### **Competition intensifies**
- **Mitigation**: Build moats (open-source community, data network effects, brand)
- **Response**: Accelerate product development, strategic M&A

#### **Market shifts (AI disruption)**
- **Mitigation**: Stay at forefront of AI/ML, flexible architecture
- **Response**: Pivot product strategy, leverage existing customer base

### Operational Risks

#### **Scaling challenges**
- **Mitigation**: Hire experienced operators, invest in systems/processes
- **Response**: Slow growth if needed, focus on fundamentals

#### **Key person risk**
- **Mitigation**: Build strong leadership team, document processes
- **Response**: Succession planning, cross-training

### Financial Risks

#### **Burn rate too high**
- **Mitigation**: Monitor metrics closely, maintain runway
- **Response**: Cut costs, raise capital, focus on profitability

#### **Revenue concentration**
- **Mitigation**: Diversify customer base, multiple revenue streams
- **Response**: Expand market, add products

---

## Milestones & Metrics (Years 3-5)

### Year 3 Milestones
- âœ… $6.5M-7M combined revenue
- âœ… 2,500-4,000 total customers/users
- âœ… 30-41 team members
- âœ… Profitable or break-even
- âœ… International expansion (eyentell)
- âœ… 20+ enterprise customers (cognisom)

### Year 4 Milestones
- âœ… $12M-18M combined revenue
- âœ… 5,000-7,000 total customers/users
- âœ… 50-65 team members
- âœ… 15-20% EBITDA margin
- âœ… FDA clearance path (cognisom)
- âœ… SOC 2 Type II (eyentell)

### Year 5 Milestones
- âœ… $18M-30M combined revenue
- âœ… 8,000-12,000 total customers/users
- âœ… 65-95 team members
- âœ… 15-25% EBITDA margin
- âœ… Market leadership in both categories
- âœ… Strategic optionality (IPO/acquisition ready)

---

## Investment Requirements

### Year 2-3: Series A (Optional)
**Amount**: $5M-10M  
**Timing**: Month 18-24  
**Use of funds**:
- Team hiring (15-25 people)
- Product development
- Sales & marketing
- International expansion

**Valuation**: $20M-40M pre-money  
**Dilution**: 20-30%

### Year 4-5: Series B (If pursuing growth)
**Amount**: $20M-50M  
**Timing**: Month 36-48  
**Use of funds**:
- Aggressive hiring (50-100 people)
- International expansion
- M&A opportunities
- Infrastructure scaling

**Valuation**: $100M-300M pre-money  
**Dilution**: 15-25%

### Alternative: Bootstrap to Profitability
**Strategy**: Grow organically with revenue
- Slower growth (30-50% vs 100%+)
- Maintain control (no dilution)
- Focus on profitability
- Strategic flexibility

---

## Conclusion

### The Opportunity

eyentelligence is positioned to build **two category-defining platforms**:

1. **cognisom**: The GPU-accelerated standard for cellular biology simulation
2. **eyentell**: The privacy-first AI platform for trusted professionals

### The Path

**Year 1**: Validate technology and market fit  
**Year 2**: Achieve product-market fit and early revenue ($2M-3M)  
**Year 3**: Scale operations and establish market position ($6M-7M)  
**Year 4**: Dominate respective markets ($12M-18M)  
**Year 5**: Create strategic optionality ($18M-30M)

### The Outcome

By Year 5, eyentelligence will be:
- **Revenue**: $18M-30M annually
- **Customers**: 10,000+ across both platforms
- **Team**: 65-95 world-class employees
- **Position**: Market leader in both categories
- **Options**: IPO, strategic acquisition, or continued independent growth

### The Differentiator

**Dual-platform strategy** provides:
- **Diversification**: Multiple revenue streams, reduced risk
- **Synergy**: Shared technology, team, infrastructure
- **Narrative**: Unique positioning ("cells to minds")
- **Optionality**: Multiple paths to liquidity

### The Ask

**For investors**: Join us in building two transformative platforms  
**For customers**: Partner with us to shape the future  
**For talent**: Help us solve the hardest problems in biology and AI  
**For partners**: Collaborate to create category-defining solutions

---

**The future is mechanistic AI that understands communication at every scaleâ€”from cellular recognition to human connection. Let's build it together.** ðŸš€

---

## Appendices

### A. Detailed Financial Model
*See separate Excel model for full P&L, cash flow, and balance sheet projections*

### B. Market Analysis
*See separate market research document for TAM/SAM/SOM analysis*

### C. Competitive Analysis
*See separate competitive landscape document*

### D. Technical Roadmap
*See separate technical architecture and roadmap documents*

### E. Go-to-Market Playbooks
*See separate GTM strategy documents for each platform*

---

**Document Version**: 1.0  
**Last Updated**: November 2024  
**Next Review**: Quarterly
